Type iib hyperlipoproteinemia is caused by mutation in the receptor-binding domain of apolipoprotein b-100 which is a major component of low-density lipoproteins and very-low-density lipoproteins resulting in reduced clearance of these lipoproteins. it is characterized by both hypercholesterolemia and hypertriglyceridemia (combined hyperlipidemia).